Navigation Links
Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
Date:12/18/2007

Initial Results Expected to be Reported in Q1 2008

PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed its target patient enrollment in its Phase 2a proof-of-concept clinical trial with AZ-104 (Staccato(R) loxapine) in patients with migraine headache. AZ-104 is a lower dose version of AZ-004, which is being developed to treat acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 and AZ-104 are being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.

The Phase 2a clinical trial was an in-clinic, multi-center, randomized, double-blind, single-administration, placebo-controlled study in approximately 160 migraine patients with or without aura. Three doses of AZ-104 (1.25, 2.5 and 5 mg) were evaluated against placebo in the clinical trial. Using the IHS (International Headache Society) 4-point rating scale, the primary efficacy endpoint was pain-relief response at 2 hours post-administration. Secondary efficacy endpoints for the trial included additional pain response assessments and other symptom assessments at various time points. Safety evaluations were made throughout the clinical trial period.

"Loxapine's mechanism of action is unique. It acts as an antagonist at D2 dopamine receptors and also acts as an antagonist at 5-HT2 serotonergic receptors. This dual mechanism of pharmacological action makes AZ-104 an interesting product candidate to study in this proof-of-concept clinical trial in patients with migraine," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza and chairman of the Symphony Allegro Develop
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...karia Holdings, Inc. today announced that it has b...ersey Technology Council (NJTC), a 1,200-member no...rt, networking opportunities, information and advo...karia earned the award based on criteria including...ision. , , "We are delighted that the New J...
(Date:11/20/2008)...T PHASE III TRIAL SHOW SIGNIFICANT, DECREASES...CTION, IN, FIBROMYALGI... Belgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz ...uronext Brussels: UCB),announced today positive p...,Phase III pivotal clinical trials of sodium oxyba...
(Date:11/20/2008)...- Radius Health ("Radius") announced today that it...d institutional financing round, increasing total ... amount raised since the company,s inception to $1... participated in the financing, led by MPM Bio IV ...Wellcome Trust, HealthCare Ventures, Oxford Biosci...
(Date:11/19/2008)...re-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mill...of,Takeda Pharmaceutical Company Limited (TSE: 40... 3 MONET1 trial evaluating motesanib (AMG 706) in,...he first-line treatment of,advanced non-small cel...ed,following a planned safety data review of 600 ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 1Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 2Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 3Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 4Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 5Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 6Regular tipple may curb risk of rheumatoid arthritis 21104 1Regular tipple may curb risk of rheumatoid arthritis 21104 2Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 1Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 1MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 3
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)... Va., Nov. 21 The Gener... following statement today from,GPhA President an...Commission,(FTC) roundtable on "Emerging Health C...e mere fact that the FTC is conducting this roundt...uring that consumers have access to safe and,affo...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2
...umpy old man’, ‘old fogies’ and other such, this i...ersity//. Surprisingly, it’s older people who are ... that people become more positive as they get olde...d to have a "glass empty" view of the world. As ...
...that can keep arteries healthy and prevent heart a...ast one orange// a day could keep cardiac disease ...anones that reduced blood cholesterol levels by 20...on rats, reported the online edition of Daily Mail...
... stress better than those live single, says a stud...r//. Popular perception is that single people have...ws that being in a loving relationship makes it ea...ains of working life, reported online edition of D...
... at Weill Cornell Medical College could prove a po...The compound, called SS31, is able to cross the bl...molecule recently linked to stroke-related tissue ...s, we found that exposing mice to SS31 after an in...
Other Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: